Evenity romosozumab APPROVED
Drug Profile
ModalityAntibody
RouteSC
Therapy AreaCVRM
Launch2019-04-09
US LOE2032-04-01
Peak Sales Est$3500M
Formulations[{"id":"evenity-sc","doses":"210mg (2x105mg)","route":"SC","device":"Pre-filled syringe (2 injection
Companies
AMGN (CO_DEVELOPER)50%
UCB (ORIGINATOR)50%
Mechanism: Sclerostin inhibitor
Expert: Humanized monoclonal antibody that binds sclerostin, inhibiting its negative regulation of the Wnt signaling pathway, thereby increasing bone formation and decreasing bone resorption.
Everyday: Blocks sclerostin, a protein that stops bone formation, allowing bones to grow stronger.
Targets: ["SOST"]
Revenue History
PeriodRevenue ($M)
2024$1,563M
2025$2,100M
Q4 2024$431M
Q4 2025$599M
Programs (1)
IndicationStageKey StudyRegional Status
Postmenopausal osteoporosisAPPROVEDFRAME, ARCH[{"stage":"APPROVED","region":"US","approval_date":"2019-04-09"},{"stage":"APPRO
Upcoming Catalysts (1)
Evenity - Commercial Uptake (with Amgen) 2026
Notes
+34% YoY to $2.1B. Strong growth driven by increasing osteoporosis awareness and bone-building differentiation vs anti-resorptives. Co-developed with UCB.
Data from Supabase · Updated 2026-03-24